The ability to control enzyme cascades entrapped in a nanoporous electrode material (the "Electrochemical Leaf", e-Leaf) has been exploited to gain detailed kinetic insight into the mechanism of an anti-cancer drug. Ivosidenib, used to treat acute myeloid leukemia, acts on a common cancer-linked variant of isocitrate dehydrogenase 1 (IDH1 R132H) inhibiting its "gain-of-function" activity-the undesired reduction of 2-oxoglutarate (2OG) to the oncometabolite 2-hydroxyglutarate (2HG). The e-Leaf quantifies the kinetics of IDH1 R132H inhibition across a wide and continuous range of conditions, efficiently revealing factors underlying the inhibitor residence time. Selective inhibition of IDH1 R132H by Ivosidenib and another inhibitor, Novartis 224, is readily resolved as a two-stage process whereby initial rapid non-inhibitory binding is followed by a slower step to give the inhibitory complex. These kinetic features are likely present in other allosteric inhibitors of IDH1/2. Such details, essential for understanding inhibition mechanisms, are not readily resolved in conventional steady-state kinetics or by techniques that rely only on measuring binding. Extending the new method and analytical framework presented here to other enzyme systems will be straightforward and should rapidly reveal insight that is difficult or often impossible to obtain using other methods.
Transducing the tightly‐channeled catalytic activity of “nanoconfined” enzyme cascades into electrical current affords a powerful and novel way to observe specific enzyme reactions, directly and in real time. Here, the “Electrochemical Leaf” is used to extract detailed kinetic and mechanistic information on the inhibitory action of a high‐profile cancer drug that inhibits a common cancer‐associated variant of isocitrate dehydrogenase 1 (IDH1).
Keywords: Enzyme Inhibition; Enzyme Mechanism; Isocitrate Dehydrogenase; Kinetics; Nanoconfinement.
© 2023 The Authors. Angewandte Chemie published by Wiley-VCH GmbH.